Exact Mass: 652.3740002

Exact Mass Matches: 652.3740002

Found 239 metabolites which its exact mass value is equals to given mass value 652.3740002, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Metocurine

NCGC00181151-01

C40H48N2O6+2 (652.3512188)


D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents > D009466 - Neuromuscular Blocking Agents C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant

   
   

Metocurine

(1S,16R)-9,10,21,25-tetramethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.2³,⁶.1⁸,¹².1¹⁸,²².0²⁷,³¹.0¹⁶,³⁴]hexatriaconta-3,5,8(34),9,11,18(33),19,21,24,26,31,35-dodecaene-15,30-diium

C40H48N2O6 (652.3512188)


Metocurine is only found in individuals that have used or taken this drug. It is a non-depolarizing muscle relaxant. Patients on chronic anticonvulsant drugs are relatively resistant to metocurine.(PMID: 9915319)Metocurine antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.

   

Notoginsenoside T1

2-({14-[(2E)-4-(3,3-dimethyloxiran-2-yl)-4-hydroxybut-2-en-2-yl]-5,16-dihydroxy-2,6,6,10,11-pentamethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-8-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol

C36H60O10 (652.418626)


Notoginsenoside T1 is found in tea. Notoginsenoside T1 is a constituent of Panax notoginseng (sanchi) roots. Constituent of Panax notoginseng (sanchi) roots. Notoginsenoside T1 is found in tea.

   

Uzarigenin 3-[xylosyl-(1->2)-rhamnoside]

4-[5-({4,5-dihydroxy-6-methyl-3-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl}oxy)-11-hydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-yl]-2,5-dihydrofuran-2-one

C34H52O12 (652.3458592)


Uzarigenin 3-[xylosyl-(1->2)-rhamnoside] is found in fruits. Uzarigenin 3-[xylosyl-(1->2)-rhamnoside] is a constituent of Tamarindus indica (tamarind) Constituent of Tamarindus indica (tamarind). Uzarigenin 3-[xylosyl-(1->2)-rhamnoside] is found in fruits.

   

n-[2(r)-Hydroxy-1(s)-indanyl]-2(r)-phenylmethyl-4(s)-hydroxy-5-[4-[2-benzofuranylmethyl]-2(s)-[tert-butylaminocarbonyl]-piperazinyl]-pentaneamide

4-[(1-Benzofuran-2-yl)methyl]-1-{4-benzyl-2-hydroxy-4-[(2-hydroxy-2,3-dihydro-1H-inden-1-yl)-C-hydroxycarbonimidoyl]butyl}-N-tert-butylpiperazine-2-carboximidate

C39H48N4O5 (652.3624517999999)


   

PA(10:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

[(2R)-3-(decanoyloxy)-2-{[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.3740002)


PA(10:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 4-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.3740002)


PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/10:0), in particular, consists of one chain of one 4-hydroxy-docosahexaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

[(2R)-3-(decanoyloxy)-2-{[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.3740002)


PA(10:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 7-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.3740002)


PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/10:0), in particular, consists of one chain of one 7-hydroxy-docosahexaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

[(2R)-3-(decanoyloxy)-2-{[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.3740002)


PA(10:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 14-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(4Z,7Z,10Z,12E,16Z,19Z)-14-hydroxydocosa-4,7,10,12,16,19-hexaenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.3740002)


PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/10:0), in particular, consists of one chain of one 14-hydroxy-docosahexaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

[(2R)-3-(decanoyloxy)-2-{[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.3740002)


PA(10:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 17-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(4Z,7Z,10Z,13E,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.3740002)


PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/10:0), in particular, consists of one chain of one 17-hydroxy-docosahexaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

[(2R)-3-(decanoyloxy)-2-{[(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.3740002)


PA(10:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 16,17-epoxy-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoyl]oxy}propoxy]phosphonic acid

C35H57O9P (652.3740002)


PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/10:0), in particular, consists of one chain of one 16,17-epoxy-docosapentaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   
   
   
   
   
   
   
   

Sutherlandioside A

Sutherlandioside A

C36H60O10 (652.418626)


   
   

Sutherlandioside B

Sutherlandioside B

C36H60O10 (652.418626)


   
   
   
   

Cherimolacyclopeptide D

Cherimolacyclopeptide D

C29H48N8O9 (652.3544078)


   
   

20-hydroxy-11-oxomogroside I A1|20-hydroxy-11-oxomogroside IA1|3beta,20,24,25-tetra-hydroxy-(24R)-cucurbit-5-en-11-one 24-O-beta-D-glucopyranoside

20-hydroxy-11-oxomogroside I A1|20-hydroxy-11-oxomogroside IA1|3beta,20,24,25-tetra-hydroxy-(24R)-cucurbit-5-en-11-one 24-O-beta-D-glucopyranoside

C36H60O10 (652.418626)


   
   
   

cycloastragenol-3-O-glucoside|sieberoside I

cycloastragenol-3-O-glucoside|sieberoside I

C36H60O10 (652.418626)


   

1-methoxy-7,8-dimethyl-beta-naphthyl-beta-D-glucopuranosyl-4-pimaran-17-oic acid ester

1-methoxy-7,8-dimethyl-beta-naphthyl-beta-D-glucopuranosyl-4-pimaran-17-oic acid ester

C39H56O8 (652.3974976000001)


   

2-methyl-1-[2,4,6-trihydroxy-3-(3-methyl-2-butenyl)-5-[6-methyl-1-[2,4,6-trihydroxy-3-(3-methyl-2-butenyl)-5-(2-methyl-1-oxopropyl)phenyl] heptyl]phenyl]-1-butanone

2-methyl-1-[2,4,6-trihydroxy-3-(3-methyl-2-butenyl)-5-[6-methyl-1-[2,4,6-trihydroxy-3-(3-methyl-2-butenyl)-5-(2-methyl-1-oxopropyl)phenyl] heptyl]phenyl]-1-butanone

C39H56O8 (652.3974976000001)


   

(20R,24S)-epoxy-9beta,19-cyclolanostane-3beta,6alpha,16beta,25-tetrol 3-O-beta-D-glucopyranoside

(20R,24S)-epoxy-9beta,19-cyclolanostane-3beta,6alpha,16beta,25-tetrol 3-O-beta-D-glucopyranoside

C36H60O10 (652.418626)


   

petuniasterone C 7,22-dinicotinate

petuniasterone C 7,22-dinicotinate

C40H48N2O6 (652.3512188)


   

Kizutasaponin K7A

Kizutasaponin K7A

C36H60O10 (652.418626)


   
   

12??,21-Dihydroxycimigenol 3-O-??-L-arabinopyranoside

12??,21-Dihydroxycimigenol 3-O-??-L-arabinopyranoside

C35H56O11 (652.3822426)


   
   

16-O-beta-D-glucopyranosyl-3,6,16,25-tetrahydroxy-20(R),24(S)-epoxycycloartane|hareftoside D

16-O-beta-D-glucopyranosyl-3,6,16,25-tetrahydroxy-20(R),24(S)-epoxycycloartane|hareftoside D

C36H60O10 (652.418626)


   

21-O-beta-D-glucopyranosyl-3beta,16beta,21beta,23,28-pentahydroxyolean-12-en|pleurosaponin A

21-O-beta-D-glucopyranosyl-3beta,16beta,21beta,23,28-pentahydroxyolean-12-en|pleurosaponin A

C36H60O10 (652.418626)


   
   

(3beta,6beta,12beta,23S,24R,25S)-16,23:23,26-diepoxy-6,12,24,25-tetrahydroxy-9,19-cycloart-3-O-beta-D-xylopyranoside|yunnanterpene F

(3beta,6beta,12beta,23S,24R,25S)-16,23:23,26-diepoxy-6,12,24,25-tetrahydroxy-9,19-cycloart-3-O-beta-D-xylopyranoside|yunnanterpene F

C35H56O11 (652.3822426)


   
   

(20S,24R)-6-O-beta-D-glucopyranosyldammar-3-one-20,24-epoxy-6alpha,12beta,25-triol|pseudoginsenoside RT6

(20S,24R)-6-O-beta-D-glucopyranosyldammar-3-one-20,24-epoxy-6alpha,12beta,25-triol|pseudoginsenoside RT6

C36H60O10 (652.418626)


   
   

(20S)-3beta,6alpha,12beta20-tetrahydroxydammara-25-ene-24-one 20-O-beta-D-glucopyranoside|floralginsenoside Ta|ginsenoside Rh11

(20S)-3beta,6alpha,12beta20-tetrahydroxydammara-25-ene-24-one 20-O-beta-D-glucopyranoside|floralginsenoside Ta|ginsenoside Rh11

C36H60O10 (652.418626)


   
   
   

16-demethoxymethyllycaconitine|1alpha,6beta,14alpha-trimethoxy-7,8-dihydroxy-18-(2-methyl)succinylanthranoyloxyaconane

16-demethoxymethyllycaconitine|1alpha,6beta,14alpha-trimethoxy-7,8-dihydroxy-18-(2-methyl)succinylanthranoyloxyaconane

C36H48N2O9 (652.3359638)


   

(1alpha,3beta,12beta,16beta,24E)-26-O-beta-D-glucopyranoside,Cycloart-24-ene-1,3,12,16,26,-pentol

(1alpha,3beta,12beta,16beta,24E)-26-O-beta-D-glucopyranoside,Cycloart-24-ene-1,3,12,16,26,-pentol

C36H60O10 (652.418626)


   

malbrancheoside B

malbrancheoside B

C36H60O10 (652.418626)


   
   

1beta,2alpha,3beta,19alpha,23-pentahydroxyurs-12-en-28-oic acid-28-O-beta-D-xylopyranoside

1beta,2alpha,3beta,19alpha,23-pentahydroxyurs-12-en-28-oic acid-28-O-beta-D-xylopyranoside

C35H56O11 (652.3822426)


   

(20S,22S,23R,24S)-3beta,22,23-trihydroxy-3-O-(beta-D-glucopyranosyl)-32-nor-24-methyllanost-8(9)-en-30-oic acid|ulososide C

(20S,22S,23R,24S)-3beta,22,23-trihydroxy-3-O-(beta-D-glucopyranosyl)-32-nor-24-methyllanost-8(9)-en-30-oic acid|ulososide C

C36H60O10 (652.418626)


   

3-methoxy-6,8-dimethyl-beta-naphthyl-beta-D-glucopyranosyl-6-pimaran-17-oic acid ester|catharanthusopimaranoside A

3-methoxy-6,8-dimethyl-beta-naphthyl-beta-D-glucopyranosyl-6-pimaran-17-oic acid ester|catharanthusopimaranoside A

C39H56O8 (652.3974976000001)


   

30,30-dichlorocylindrocyclophane A|cylindrocyclophane A2

30,30-dichlorocylindrocyclophane A|cylindrocyclophane A2

C36H54Cl2O6 (652.3297244)


   
   
   
   
   
   
   
   
   
   
   

C34H52O12_1,5,16-Trihydroxy-26-oxo-6,7:22,26-diepoxyergost-24-en-3-yl hexopyranoside

NCGC00347778-02_C34H52O12_1,5,16-Trihydroxy-26-oxo-6,7:22,26-diepoxyergost-24-en-3-yl hexopyranoside

C34H52O12 (652.3458592)


   

C36H60O10

NCGC00380940-01_C36H60O10_

C36H60O10 (652.418626)


   

KYVML

Lys-Tyr-Val-Met-Leu

C31H52N6O7S (652.3618002000001)


   

EIRHV

Glu-Ile-Arg-His-Val

C28H48N10O8 (652.3656408)


   

PI(22:2(13Z,16Z)/0:0)

1-(13Z,16Z-docosadienoyl)-glycero-3-phospho-(1-myo-inositol)

C31H57O12P (652.3587451999999)


   

PA(13:0/20:5(5Z,8Z,11Z,14Z,17Z))

1-tridecanoyl-2-(5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl)-glycero-3-phosphate

C36H61O8P (652.4103835999999)


   

PA(15:1(9Z)/18:4(6Z,9Z,12Z,15Z))

1-(9Z-pentadecenoyl)-2-(6Z,9Z,12Z,15Z-octadecatetraenoyl)-glycero-3-phosphate

C36H61O8P (652.4103835999999)


   

PA(18:4(6Z,9Z,12Z,15Z)/15:1(9Z))

1-(6Z,9Z,12Z,15Z-octadecatetraenoyl)-2-(9Z-pentadecenoyl)-glycero-3-phosphate

C36H61O8P (652.4103835999999)


   

PA(20:5(5Z,8Z,11Z,14Z,17Z)/13:0)

1-(5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl)-2-tridecanoyl-glycero-3-phosphate

C36H61O8P (652.4103835999999)


   

Uzarigenin 3-[xylosyl-(1->2)-rhamnoside]

4-[5-({4,5-dihydroxy-6-methyl-3-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl}oxy)-11-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]-2,5-dihydrofuran-2-one

C34H52O12 (652.3458592)


   

Notoginsenoside T1

2-({14-[(2E)-4-(3,3-dimethyloxiran-2-yl)-4-hydroxybut-2-en-2-yl]-5,16-dihydroxy-2,6,6,10,11-pentamethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-8-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol

C36H60O10 (652.418626)


   

1,5,16-Trihydroxy-26-oxo-6,7:22,26-diepoxyergost-24-en-3-yl hexopyranoside

1,5,16-Trihydroxy-26-oxo-6,7:22,26-diepoxyergost-24-en-3-yl hexopyranoside

C34H52O12 (652.3458592)


   

LPI 22:2

1-(13Z,16Z-docosadienoyl)-glycero-3-phospho-(1-myo-inositol)

C31H57O12P (652.3587451999999)


   

PA 33:5

1-(6Z,9Z,12Z,15Z-octadecatetraenoyl)-2-(9Z-pentadecenoyl)-glycero-3-phosphate

C36H61O8P (652.4103835999999)


   

Aspacoside E

5beta-pregn-20-ene-3,16-diol-22-one 3-O-alpha-l-rhamnopyranosyl-(1-2)-beta-d-glucopyranoside

C34H52O12 (652.3458592)


   

BA-delta5-3beta,7beta-diol 7betaGlcNAc,24G

3beta-hydroxy-7beta-N-acetylglucosaminylchol-5-en-24-oylglycine

C33H52N2O11 (652.3570922)


   

Bastaxanthin C2

19,3-dihydroxy-6-oxo-7,8-didehydro-beta,kappa-caroten-3-yl sulphate

C38H52O7S (652.3433562)


   

Amyloid β-Protein (16-20) trifluoroacetate salt

Amyloid β-Protein (16-20) trifluoroacetate salt

C35H52N6O6 (652.3948132)


β-Amyloid peptide(16-20) is a amino acid sequences (KLVFF) of Amyloid-β (Abeta). β-Amyloid peptide(16-20) is an effective inhibitor of Abeta fibril formation, with RG-/-GR-NH2 residues added at N- and C-terminal ends to aid solubility)[1].

   

Metoprolol succinate

Metroprolol succinate

C34H56N2O10 (652.3934756)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Metoprolol succinate is an orally active, selective β1-adrenoceptor antagonist. Metoprolol succinate shows anti-inflammation, antitumor and anti-angiogenic properties[1][2][3].

   

N,N-DI-P-TOLYL-N,N-BIS-(4-BUTYLPHENYL)-PHENANTHRENE-9,10-DIAMINE

N,N-DI-P-TOLYL-N,N-BIS-(4-BUTYLPHENYL)-PHENANTHRENE-9,10-DIAMINE

C48H48N2 (652.3817288)


   

(2S)-4-(1-benzofuran-2-ylmethyl)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butylpiperazine-2-carboxamide

(2S)-4-(1-benzofuran-2-ylmethyl)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butylpiperazine-2-carboxamide

C39H48N4O5 (652.3624517999999)


   

PA(10:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

PA(10:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C35H57O9P (652.3740002)


   

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/10:0)

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/10:0)

C35H57O9P (652.3740002)


   

PA(10:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

PA(10:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C35H57O9P (652.3740002)


   

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/10:0)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/10:0)

C35H57O9P (652.3740002)


   

PA(10:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

PA(10:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C35H57O9P (652.3740002)


   

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/10:0)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/10:0)

C35H57O9P (652.3740002)


   

PA(10:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

PA(10:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C35H57O9P (652.3740002)


   

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/10:0)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/10:0)

C35H57O9P (652.3740002)


   

PA(10:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

PA(10:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C35H57O9P (652.3740002)


   

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/10:0)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/10:0)

C35H57O9P (652.3740002)


   

2-[[(2R)-3-acetyloxy-2-[7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]-6-oxoheptanoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-3-acetyloxy-2-[7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]-6-oxoheptanoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H55NO12P+ (652.34617)


   

2-[[(2R)-2-acetyloxy-3-[7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]-6-oxoheptanoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-2-acetyloxy-3-[7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]-6-oxoheptanoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H55NO12P+ (652.34617)


   

2-[[(2R)-3-acetyloxy-2-[(Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]oxan-3-yl]hept-5-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-3-acetyloxy-2-[(Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]oxan-3-yl]hept-5-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H55NO12P+ (652.34617)


   

2-[[(2R)-2-acetyloxy-3-[(Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]oxan-3-yl]hept-5-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-2-acetyloxy-3-[(Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]oxan-3-yl]hept-5-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H55NO12P+ (652.34617)


   

Ethidium homodimer tetracation

Ethidium homodimer tetracation

C41H48N8+4 (652.4001728)


   

1-cyclohexyl-3-[(3R,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-9-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

1-cyclohexyl-3-[(3R,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-9-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C37H56N4O6 (652.4199636000001)


   

1-[(3S,9S,10R)-9-[[cyclohexylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-methoxyphenyl)urea

1-[(3S,9S,10R)-9-[[cyclohexylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-methoxyphenyl)urea

C37H56N4O6 (652.4199636000001)


   

N-[(3R,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(pyridin-4-ylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

N-[(3R,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(pyridin-4-ylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C35H48N4O6S (652.3294387999999)


   

2-[[(2R)-2-[(E)-6-carboxy-4-hydroxyhex-5-enoyl]oxy-3-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-2-[(E)-6-carboxy-4-hydroxyhex-5-enoyl]oxy-3-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C31H59NO11P+ (652.3825534)


   

3,6-diamino-N-[[(8Z)-15-amino-11-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide

3,6-diamino-N-[[(8Z)-15-amino-11-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide

C25H44N14O7 (652.3517234000001)


   

[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (13Z,16Z)-docosa-13,16-dienoate

[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (13Z,16Z)-docosa-13,16-dienoate

C31H57O12P (652.3587451999999)


   
   
   
   
   
   
   
   

[1-acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (Z)-tridec-9-enoate

[1-acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (Z)-tridec-9-enoate

C30H52O15 (652.3306042)


   
   
   
   
   
   
   
   
   

[1-propanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

[1-propanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

C36H60O10 (652.418626)


   

[1-heptanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

[1-heptanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C36H60O10 (652.418626)


   

[1-nonanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

[1-nonanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C36H60O10 (652.418626)


   

[1-pentanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

[1-pentanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C36H60O10 (652.418626)


   

[1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

[1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C36H60O10 (652.418626)


   

(1-phosphonooxy-3-tridecanoyloxypropan-2-yl) (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

(1-phosphonooxy-3-tridecanoyloxypropan-2-yl) (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C36H61O8P (652.4103835999999)


   

[1-[(Z)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

[1-[(Z)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C36H61O8P (652.4103835999999)


   

[1-phosphonooxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

[1-phosphonooxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C36H61O8P (652.4103835999999)


   

(1-phosphonooxy-3-undecanoyloxypropan-2-yl) (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

(1-phosphonooxy-3-undecanoyloxypropan-2-yl) (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C36H61O8P (652.4103835999999)


   

[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropyl] (Z)-heptadec-9-enoate

[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropyl] (Z)-heptadec-9-enoate

C36H61O8P (652.4103835999999)


   

[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-phosphonooxypropyl] (9Z,12Z)-heptadeca-9,12-dienoate

[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-phosphonooxypropyl] (9Z,12Z)-heptadeca-9,12-dienoate

C36H61O8P (652.4103835999999)


   

(1-pentadecanoyloxy-3-phosphonooxypropan-2-yl) (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

(1-pentadecanoyloxy-3-phosphonooxypropan-2-yl) (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C36H61O8P (652.4103835999999)


   

2-[[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(E)-undec-4-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(E)-undec-4-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C35H59NO8P+ (652.3978084)


   

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

C36H61O8P (652.4103835999999)


   

[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C36H61O8P (652.4103835999999)


   

[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C36H61O8P (652.4103835999999)


   

[(2R)-1-phosphonooxy-3-undecanoyloxypropan-2-yl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

[(2R)-1-phosphonooxy-3-undecanoyloxypropan-2-yl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

C36H61O8P (652.4103835999999)


   

[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C36H61O8P (652.4103835999999)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C34H53O10P (652.3376168)


   

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (E)-heptadec-7-enoate

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (E)-heptadec-7-enoate

C36H61O8P (652.4103835999999)


   

[(2R)-1-phosphonooxy-3-undecanoyloxypropan-2-yl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

[(2R)-1-phosphonooxy-3-undecanoyloxypropan-2-yl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C36H61O8P (652.4103835999999)


   

[(2R)-3-phosphonooxy-2-undecanoyloxypropyl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

[(2R)-3-phosphonooxy-2-undecanoyloxypropyl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

C36H61O8P (652.4103835999999)


   

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

C36H61O8P (652.4103835999999)


   

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] heptadecanoate

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] heptadecanoate

C36H61O8P (652.4103835999999)


   

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] (8E,11E,14E)-heptadeca-8,11,14-trienoate

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] (8E,11E,14E)-heptadeca-8,11,14-trienoate

C36H61O8P (652.4103835999999)


   

[1-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(E)-undec-4-enoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

[1-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(E)-undec-4-enoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C36H60O10 (652.418626)


   

[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C36H61O8P (652.4103835999999)


   

[(2R)-3-phosphonooxy-2-undecanoyloxypropyl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

[(2R)-3-phosphonooxy-2-undecanoyloxypropyl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C36H61O8P (652.4103835999999)


   

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (11E,14E)-heptadeca-11,14-dienoate

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (11E,14E)-heptadeca-11,14-dienoate

C36H61O8P (652.4103835999999)


   

[1-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

[1-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C36H60O10 (652.418626)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(6E,9E)-dodeca-6,9-dienoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(6E,9E)-dodeca-6,9-dienoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C34H53O10P (652.3376168)


   

2-[[2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-pentanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-pentanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C35H59NO8P+ (652.3978084)


   

1-(13Z,16Z-docosadienoyl)-glycero-3-phospho-(1-myo-inositol)

1-(13Z,16Z-docosadienoyl)-glycero-3-phospho-(1-myo-inositol)

C31H57O12P (652.3587451999999)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

n-(1-oxo-1-{[(8z,10z,16z)-3,15,24-trihydroxy-5,22-dimethoxy-14,16-dimethyl-2-azabicyclo[18.3.1]tetracosa-1(23),2,6,8,10,16,20(24),21-octaen-13-yl]oxy}propan-2-yl)cyclohexanecarboximidic acid

n-(1-oxo-1-{[(8z,10z,16z)-3,15,24-trihydroxy-5,22-dimethoxy-14,16-dimethyl-2-azabicyclo[18.3.1]tetracosa-1(23),2,6,8,10,16,20(24),21-octaen-13-yl]oxy}propan-2-yl)cyclohexanecarboximidic acid

C37H52N2O8 (652.3723472)


   

{11-ethyl-8,9-dihydroxy-4,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methyl 2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoate

{11-ethyl-8,9-dihydroxy-4,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methyl 2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoate

C36H48N2O9 (652.3359638)


   

2-[(6s,9s,12s,15s,18s,23as)-1,4,7,10,13,16-hexahydroxy-18-[(1r)-1-hydroxyethyl]-15-isopropyl-12-methyl-6-(2-methylpropyl)-19-oxo-3h,6h,9h,12h,15h,18h,21h,22h,23h,23ah-pyrrolo[1,2-a]1,4,7,10,13,16,19-heptaazacyclohenicosan-9-yl]ethanimidic acid

2-[(6s,9s,12s,15s,18s,23as)-1,4,7,10,13,16-hexahydroxy-18-[(1r)-1-hydroxyethyl]-15-isopropyl-12-methyl-6-(2-methylpropyl)-19-oxo-3h,6h,9h,12h,15h,18h,21h,22h,23h,23ah-pyrrolo[1,2-a]1,4,7,10,13,16,19-heptaazacyclohenicosan-9-yl]ethanimidic acid

C29H48N8O9 (652.3544078)


   

[(1r,2r,4s,5s,6r,7s,8r,9s,10s,11r,13s,15r,17r)-5,6,7,8,9-pentahydroxy-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-8-yl]methyl (2e,4e,6e)-deca-2,4,6-trienoate

[(1r,2r,4s,5s,6r,7s,8r,9s,10s,11r,13s,15r,17r)-5,6,7,8,9-pentahydroxy-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-8-yl]methyl (2e,4e,6e)-deca-2,4,6-trienoate

C37H48O10 (652.3247308)


   

(1r,2r,6s,7s,8r,10s,11s,12r,14s,16s,17r,18r)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-14-nonyl-5-oxo-16-(prop-1-en-2-yl)-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl benzoate

(1r,2r,6s,7s,8r,10s,11s,12r,14s,16s,17r,18r)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-14-nonyl-5-oxo-16-(prop-1-en-2-yl)-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl benzoate

C37H48O10 (652.3247308)


   

[(2s,4r,5r,7s,9r,10s,11s,13s,14r,15s,23s,25r)-10,11-dihydroxy-9-(hydroxymethyl)-13,15-dimethyl-12-oxo-4-(prop-1-en-2-yl)-8,24,26,27-tetraoxaheptacyclo[12.10.1.1⁴,²³.1⁵,²³.0¹,⁶.0⁷,⁹.0¹¹,²⁵]heptacosan-2-yl]methyl benzoate

[(2s,4r,5r,7s,9r,10s,11s,13s,14r,15s,23s,25r)-10,11-dihydroxy-9-(hydroxymethyl)-13,15-dimethyl-12-oxo-4-(prop-1-en-2-yl)-8,24,26,27-tetraoxaheptacyclo[12.10.1.1⁴,²³.1⁵,²³.0¹,⁶.0⁷,⁹.0¹¹,²⁵]heptacosan-2-yl]methyl benzoate

C37H48O10 (652.3247308)


   

(1s,2r,3r,5r,10r,11r,14r,15s)-2,6,6,10-tetramethyl-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-15-[(2s,4r,5s)-4,5,6-trihydroxy-6-methylheptan-2-yl]pentacyclo[12.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]octadecan-7-one

(1s,2r,3r,5r,10r,11r,14r,15s)-2,6,6,10-tetramethyl-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-15-[(2s,4r,5s)-4,5,6-trihydroxy-6-methylheptan-2-yl]pentacyclo[12.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]octadecan-7-one

C36H60O10 (652.418626)


   

(2r,3r,4s,5s,6r)-2-{[(1s,3r,6s,9s,11s,12s,14s,15r,16r)-6,14-dihydroxy-15-[(2r,5s)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-9-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2r,3r,4s,5s,6r)-2-{[(1s,3r,6s,9s,11s,12s,14s,15r,16r)-6,14-dihydroxy-15-[(2r,5s)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-9-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C36H60O10 (652.418626)


   

6,10-dihydroxy-15-(5-hydroxy-6-methyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl)-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-4-one

6,10-dihydroxy-15-(5-hydroxy-6-methyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl)-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-4-one

C36H60O10 (652.418626)


   

(6r)-6-[(1s)-1-[(1s,2s,4s,5r,7s,9s,10s,11s,14r,15r,18s)-5,9-dihydroxy-10,14-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-oxapentacyclo[9.7.0.0²,⁴.0⁵,¹⁰.0¹⁴,¹⁸]octadecan-15-yl]ethyl]-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one

(6r)-6-[(1s)-1-[(1s,2s,4s,5r,7s,9s,10s,11s,14r,15r,18s)-5,9-dihydroxy-10,14-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-oxapentacyclo[9.7.0.0²,⁴.0⁵,¹⁰.0¹⁴,¹⁸]octadecan-15-yl]ethyl]-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one

C34H52O12 (652.3458592)


   

(2s)-2-[(3s,3as,5ar,5br,7ar,8s,9s,11ar,11br,13ar,13bs)-9-hydroxy-5a,5b,8,11a,13b-pentamethyl-8-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-hexadecahydrocyclopenta[a]chrysen-3-yl]-2-hydroxypropanoic acid

(2s)-2-[(3s,3as,5ar,5br,7ar,8s,9s,11ar,11br,13ar,13bs)-9-hydroxy-5a,5b,8,11a,13b-pentamethyl-8-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-hexadecahydrocyclopenta[a]chrysen-3-yl]-2-hydroxypropanoic acid

C36H60O10 (652.418626)


   

15-(5,6-dihydroxy-6-methylheptan-2-yl)-14-hydroxy-7,7,12,16-tetramethyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-9-one

15-(5,6-dihydroxy-6-methylheptan-2-yl)-14-hydroxy-7,7,12,16-tetramethyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-9-one

C36H60O10 (652.418626)


   

(2r,3r,4s,5s,6r)-2-{[(1s,3r,6s,8r,9s,11s,12s,14s,15r,16r)-6,14-dihydroxy-15-[(2r,5s)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-9-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2r,3r,4s,5s,6r)-2-{[(1s,3r,6s,8r,9s,11s,12s,14s,15r,16r)-6,14-dihydroxy-15-[(2r,5s)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-9-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C36H60O10 (652.418626)


   

(2s,3s,4s,5s,6r)-2-({2-[(2s,4as,8as)-6-[(3s,4ar,5r,6ar,7r,9ar,9bs)-5-hydroxy-3-(2-hydroxypropan-2-yl)-6a,9b-dimethyl-decahydroindeno[5,4-b]pyran-7-yl]-4a-methyl-2,3,4,7,8,8a-hexahydro-1-benzopyran-2-yl]propan-2-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol

(2s,3s,4s,5s,6r)-2-({2-[(2s,4as,8as)-6-[(3s,4ar,5r,6ar,7r,9ar,9bs)-5-hydroxy-3-(2-hydroxypropan-2-yl)-6a,9b-dimethyl-decahydroindeno[5,4-b]pyran-7-yl]-4a-methyl-2,3,4,7,8,8a-hexahydro-1-benzopyran-2-yl]propan-2-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol

C36H60O10 (652.418626)


   

{3,4,5-trihydroxy-6-[(3-methoxy-5,7-dimethylnaphthalen-2-yl)oxy]oxan-2-yl}methyl 7-ethyl-1,1,7-trimethyl-decahydro-2h-phenanthrene-4a-carboxylate

{3,4,5-trihydroxy-6-[(3-methoxy-5,7-dimethylnaphthalen-2-yl)oxy]oxan-2-yl}methyl 7-ethyl-1,1,7-trimethyl-decahydro-2h-phenanthrene-4a-carboxylate

C39H56O8 (652.3974976000001)


   

2-(hydroxymethyl)-6-{[1,6,10-trihydroxy-3a-(hydroxymethyl)-3-isopropyl-5a,8,8,11a,13a-pentamethyl-1h,2h,3h,4h,5h,5bh,6h,7h,7ah,9h,10h,11h,13h,13bh-cyclopenta[a]chrysen-9-yl]oxy}oxane-3,4,5-triol

2-(hydroxymethyl)-6-{[1,6,10-trihydroxy-3a-(hydroxymethyl)-3-isopropyl-5a,8,8,11a,13a-pentamethyl-1h,2h,3h,4h,5h,5bh,6h,7h,7ah,9h,10h,11h,13h,13bh-cyclopenta[a]chrysen-9-yl]oxy}oxane-3,4,5-triol

C36H60O10 (652.418626)


   

methyl 8-hydroxy-7-(octadec-9-enoyloxy)-5-oxo-2,9-bis(prop-1-en-2-yl)-4,14-dioxatricyclo[9.2.1.1³,⁶]pentadeca-1(13),6(15),11-triene-12-carboxylate

methyl 8-hydroxy-7-(octadec-9-enoyloxy)-5-oxo-2,9-bis(prop-1-en-2-yl)-4,14-dioxatricyclo[9.2.1.1³,⁶]pentadeca-1(13),6(15),11-triene-12-carboxylate

C39H56O8 (652.3974976000001)


   

2-({6,14-dihydroxy-15-[5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-9-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol

2-({6,14-dihydroxy-15-[5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-9-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol

C36H60O10 (652.418626)


   

(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl (1r,2r,4as,6as,6br,8ar,9r,10r,11r,12s,12ar,12bs,14bs)-1,10,11,12-tetrahydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl (1r,2r,4as,6as,6br,8ar,9r,10r,11r,12s,12ar,12bs,14bs)-1,10,11,12-tetrahydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C35H56O11 (652.3822426)


   

2-({1-[4-(3,3-dimethyloxiran-2-yl)-4-hydroxybut-2-en-2-yl]-7,11-dihydroxy-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-5-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol

2-({1-[4-(3,3-dimethyloxiran-2-yl)-4-hydroxybut-2-en-2-yl]-7,11-dihydroxy-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-5-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol

C36H60O10 (652.418626)


   

3,4,5-trihydroxyoxan-2-yl 1,10,11,12-tetrahydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

3,4,5-trihydroxyoxan-2-yl 1,10,11,12-tetrahydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C35H56O11 (652.3822426)


   

(2s)-2-({[(2s)-1-[(2s)-2-({[(2s)-1-[(2s)-2-{[(2s)-2-amino-1-hydroxy-3-methylbutylidene]amino}-4-methylpentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylbutanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)pentanedioic acid

(2s)-2-({[(2s)-1-[(2s)-2-({[(2s)-1-[(2s)-2-{[(2s)-2-amino-1-hydroxy-3-methylbutylidene]amino}-4-methylpentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylbutanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)pentanedioic acid

C31H52N6O9 (652.3795582)


   

2-{[14-hydroxy-16-(hydroxymethyl)-15-[5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12-trimethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-6-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

2-{[14-hydroxy-16-(hydroxymethyl)-15-[5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12-trimethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-6-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C36H60O10 (652.418626)